Evidence map›Paper›PMID 29983511›Full record

ArticleEthiopian journal of health sciences2018

Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.

Yogender Shokeen, Neeta Raj Sharma, Abhishek Vats, Vibha Taneja, Sachin Minhas, Mayank Jauhri, Satish Sankaran, Shyam Aggarwal

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ethiopian journal of health sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Yogender ShokeenDepartment of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Neeta Raj SharmaDepartment of Pediatrics and Child Health and Pediatric Emergency Consultant, School of Medicine, Addis Ababa University, Ethiopia; School of Bio-Engineering and Biosciences, Lovely Professional University, Jalandhar, Punjab, India.
Abhishek VatsDepartment of Research, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Vibha TanejaDepartment of Research, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Sachin MinhasDepartment of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Mayank JauhriDepartment of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Satish SankaranStrand Center for Genomics and Personalized Medicine. UAS Alumini Building, Veterinary College Campus, Bellary Road, Hebbal, Bangalore, India.
Shyam AggarwalDepartment of Medical Oncology, Sir Ganga Ram Hospital, Rajinder Nagar, Delhi, India.
Sir Ganga Ram Hospital · INLovely Professional University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncidence of Chronic Myeloid Leukemia (CML) is continuously increasing and expected to reach 100,000 patients every year by 2030. Though the discovery of Imatinib Mesylate (IM) has brought a paradigm shift in CML treatment, 20% patients show resistance to this tyrosine kinase inhibiter (TKI). Therefore, it is important to identify markers, which can predict the occurrence and prognosis of CML. Clinical Exome Sequencing, panel of more than 4800 genes, was performed in CML patients to identify prognostic and susceptibility markers in CML.

methodsEnrolled CML patients (n=18) were segregated as IM responders (n=10) and IM failures (n=8) as per European Leukemia Net (ELN), 2013 guidelines. Healthy controls (n=5) were also enrolled. DNA from blood of subjects was subjected to Next Generation Sequencing. Rare mutations present in one patient group and absent in another group were considered as prognostic markers, whereas mutations present in more than 50% patients were considered as susceptibility markers.

resultMutations in genes associated with cancer related functions were found in different patient groups. Four variants: rs116201358, rs4014596, rs52897880 and rs2274329 in C8A, UNC93B1, APOH and CA6 genes, respectively, were present in IM responders; whereas rs4945 in MFGE8 was present in IM failures. Mutations in HLA-DRB1 (rs17878951), HLA-DRB5 (rs137863146), RPHN2 (rs193179333), CYP2F1 (rs116958555), KCNJ12 (rs76684759) and FUT3 (rs151218854) were present as susceptibility markers.

conclusionThe potential genetic markers discovered in this study can help in predicting response to IM as frontline therapy. Susceptibility markers may also be used as panel for individuals prone to have CML.

Indexed as

Genes, NeoplasmMutationAdultAntigens, SurfaceAntineoplastic AgentsCarbonic AnhydrasesDrug Resistance, NeoplasmHigh-Throughput Nucleotide SequencingHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMembrane Transport ProteinsMiddle AgedMilk ProteinsPrognosisProtein Kinase InhibitorsAntigens, SurfaceAntineoplastic AgentsCarbonic Anhydrasescarbonic anhydrase VIImatinib MesylateMembrane Transport ProteinsMFGE8 protein, humanMilk ProteinsProtein Kinase InhibitorsUNC93B1 protein, humanChronic Myeloid LeukemiaGenetic MarkersNext Generation Sequencing (NGS)

Identifiers

PMID29983511
PMCPMC6016334
OpenAlexW2793535410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.